| 📌 The essentials Foundayo (orforglipron) was approved by the FDA on April 1, 2026 as the first non-peptide, small molecule oral GLP-1 receptor agonist for chronic weight management. It was approved 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. As part of the FDA approval letter, Eli Lilly is required to conduct several post-marketing studies. Per the FDA approval letter, these include: evaluation of major adverse cardiovascular events (MACEs) and drug-induced liver injury (DILI); assessment of delayed gastric emptying and aspiration risk; a lactation study to measure drug concentrations in breast milk; pediatric trials in patients aged 6 to 12; and pregnancy registry data. The FDA is also requiring enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases. Lilly has also separately released ACHIEVE-4 trial data showing non-inferior MACE risk compared to insulin glargine, which directly addresses the cardiovascular monitoring requirement. What this does not mean: post-marketing study requirements are routine for obesity medications and do not reflect a finding that the drug is unsafe. Foundayo was approved based on the ATTAIN clinical program data. The post-marketing studies reflect normal FDA practice of continuing safety surveillance after approval, particularly for a new molecular class with limited long-term data. |
|---|
Foundayo (orforglipron) was the most talked-about obesity drug approval of 2026. Not just because of what it is, the first oral GLP-1 receptor agonist that does not require a peptide injection and has no food or water restrictions, but because of how fast it happened. The FDA approved it 50 days after Eli Lilly submitted the NDA, making it the fastest approval of a new molecular entity since 2002, and the first new molecular entity approved under the Commissioner’s National Priority Voucher program.
What received less coverage in that story is a standard part of every major drug approval: the FDA’s post-marketing study requirements. These are the conditions attached to the approval letter specifying additional clinical studies Lilly must conduct now that the drug is on the market. A Reuters report noted some of these requirements shortly after the approval. This post looks directly at the FDA approval letter, explains what each requirement is and why it exists, and puts the requirements in context for the broader GLP-1 obesity treatment landscape.
For a full overview of what Foundayo is, how orforglipron works, and what the ATTAIN clinical trial data showed, see our main post: Foundayo: The First Once-Daily GLP-1 Pill for Weight Loss.
What Orforglipron Is and Why It Is Different
Orforglipron is a small molecule, non-peptide GLP-1 receptor agonist. Every GLP-1 receptor agonist currently approved in the United States before Foundayo, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), is based on a peptide molecule, a chain of amino acids structurally similar to the natural GLP-1 hormone. Because peptides are broken down in the stomach, most of these drugs are injectable. The one exception, Rybelsus (oral semaglutide), requires fasting for 30 minutes and a small amount of water to achieve adequate absorption.
Orforglipron is fundamentally different. It is a small organic molecule, not a peptide, that binds to and activates the same GLP-1 receptor. Its small molecule structure allows it to survive oral digestion without the absorption restrictions that peptide-based oral semaglutide requires. It can be taken at any time of day, with or without food, and without water restrictions.
This is a genuine pharmacological advance. The practicality difference between taking a once-weekly injection, taking a pill at a specific time under fasting conditions, and taking a pill whenever you want matters for real-world adherence, particularly among the more than 90% of eligible patients who are not currently on any GLP-1 therapy.
The ATTAIN clinical program demonstrated that in the ATTAIN-1 trial, patients taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4% of body weight) compared to 2.2 pounds (0.9%) with placebo. Across all trial completers regardless of dose escalation, average weight loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo. The drug also showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
What Post-Marketing Studies Are and Why They Are Routine
Before getting into the specific requirements for Foundayo, it is worth explaining what post-marketing study requirements actually are, because the framing of “FDA requires studies” can sound more alarming than it is.
Every major drug approval, particularly for new molecular entities in new drug classes, comes with post-marketing commitments and requirements. These fall into two categories:
Post-marketing commitments (PMCs): voluntary agreements where the sponsor agrees to conduct additional studies, often to explore dosing, new populations, or drug interactions.
Post-marketing requirements (PMRs): studies the FDA requires by law because specific safety questions cannot be adequately answered through nonclinical data or observational surveillance alone. They are written into the approval letter.
The distinction matters: PMRs do not mean the drug has a safety problem. They mean the FDA identified specific questions about safety in populations or settings that were not fully characterized in the pivotal trial program, and that randomized, controlled prospective data is needed to answer those questions properly. This is how responsible post-market surveillance of new drug classes works.
GLP-1 receptor agonists as a class have been subject to ongoing FDA safety monitoring since the class was first approved, including reviews of suicidal ideation reports (for which the FDA ultimately concluded in 2024 that the available evidence does not support a causal relationship between GLP-1 receptor agonists and suicidal behavior), thyroid cancer signals, and pancreatitis risk. Foundayo’s post-marketing requirements build on this established framework.
The Specific Post-Marketing Requirements for Foundayo
Based on the FDA approval letter and coverage of the approval letter contents, the following post-marketing study requirements are in place for Foundayo:
1. Cardiovascular outcomes (MACEs)
What is required: A prospective randomized trial evaluating major adverse cardiovascular events (MACEs), specifically heart attack, stroke, cardiovascular death, and unstable angina requiring hospitalization.
Why this is required: The FDA requires all new diabetes and obesity drugs to demonstrate cardiovascular safety through adequate CVOT (cardiovascular outcomes trial) data. The pivotal ATTAIN trials were designed to demonstrate weight loss efficacy and were not powered or designed as cardiovascular outcomes studies. The FDA therefore requires a dedicated CVOT to characterize the full cardiovascular risk-benefit profile of orforglipron in a larger population over longer follow-up.
Current status: Lilly has already released results from the Phase 3 ACHIEVE-4 trial (NCT05803421), which evaluated orforglipron versus insulin glargine in patients with type 2 diabetes. ACHIEVE-4 showed non-inferior risk for MACEs compared to insulin glargine and detected no safety signal for drug-induced liver injury. Lilly has indicated it plans to submit an NDA for Foundayo in type 2 diabetes by the end of Q2 2026, supported by this data. The ACHIEVE-4 results partially address the cardiovascular monitoring requirement, though the FDA will specify the scope of ongoing data requirements.
2. Drug-induced liver injury (DILI)
What is required: Enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases and periodic cumulative safety analyses.
Why this is required: New small molecule drugs, particularly those in new molecular classes, are monitored carefully for hepatotoxicity signals that may not have been apparent in pivotal trials. The ACHIEVE-4 trial found no safety signal for liver injury, but the FDA is requiring systematic prospective surveillance across the broader post-market population.
Context: Drug-induced liver injury is one of the most common reasons for post-market drug withdrawals and is a priority safety monitoring target for the FDA across drug classes. The 5-year enhanced surveillance period is a standard precautionary measure for new molecular entities.
3. Delayed gastric emptying and aspiration risk
What is required: Assessment of the drug’s effects on gastric emptying rate and associated aspiration risk, particularly relevant in the context of anesthesia and sedation procedures.
Why this is required: GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, and this effect has clinical implications for patients undergoing procedures requiring anesthesia or sedation. The American Society of Anesthesiologists has issued guidance on GLP-1 agonists in the perioperative setting, recommending holding these medications before procedures. The FDA’s requirement for orforglipron specifically is to characterize the gastric emptying effect of the oral formulation, which may have different pharmacokinetics than injectable versions.
4. Lactation study
What is required: A study measuring drug concentrations in breast milk in nursing mothers.
Why this is required: The pivotal trials excluded pregnant and breastfeeding women. The FDA requires a lactation study to determine the extent to which orforglipron is transferred into breast milk, as this directly informs prescribing decisions for women who are breastfeeding and clinicians counseling them on the drug’s safety in this setting.
5. Pediatric trials (ages 6 to 12)
What is required: Clinical trials in pediatric patients aged 6 to 12 years with obesity.
Why this is required: The Pediatric Research Equity Act (PREA) generally requires sponsors to study new drugs in pediatric populations unless a waiver is granted. The FDA waived the under-6 age group, citing limited expected use and therapeutic benefit in very young children. The 6 to 12 age group is included given that childhood and adolescent obesity is a significant clinical problem and clinicians will eventually prescribe this drug in younger patients.
6. Pregnancy registry
What is required: A structured pregnancy exposure registry to capture outcomes in women who become pregnant while taking Foundayo.
Why this is required: GLP-1 medications should be discontinued before attempting conception because of potential fetal effects, but unintended pregnancies during treatment are well documented across this drug class. The pregnancy registry will systematically capture data on fetal outcomes in women with inadvertent first-trimester exposure, building a real-world safety database that cannot be generated from controlled trials.
| Hair loss: a side effect, not a post-marketing study requirement The stub post on this topic framed hair loss as equivalent to the post-marketing study requirements above. This needs clarification. Hair loss is listed as a common side effect in the Foundayo prescribing information, alongside nausea, constipation, diarrhea, and other GI effects. It was observed in the ATTAIN trials and is included in the approved label. It is not a specific named post-marketing study requirement in the same category as the CVOT or DILI monitoring. Hair loss has been observed with GLP-1 medications more broadly and is believed to be related to the physiological stress of rapid weight loss (telogen effluvium) rather than a direct drug effect. Patients who experience hair loss on Foundayo should discuss it with their prescriber; it is typically reversible as weight stabilizes. |
|---|
Why This Pattern Is Consistent With the CNPV Approval Context
The speed of Foundayo’s approval under the CNPV program, 50 days from NDA submission, is directly relevant to understanding why the post-marketing study package is robust. The CNPV program compresses FDA review timelines dramatically but does not reduce the evidentiary standard for approval. For a novel molecular entity in a new drug class, some safety questions that would normally be answered in a longer review process are instead addressed through post-market commitments.
This is not unique to Foundayo. Wegovy HD (semaglutide 7.2 mg), which was also approved under the CNPV program, similarly came with post-marketing monitoring requirements. The CNPV program approval speed and the post-marketing study requirements are two parts of the same regulatory approach: approve based on strong efficacy and acceptable safety from the clinical program, then require prospective data to fill the remaining gaps systematically.
The FDA’s approach to Foundayo reflects a broader evolution in how it handles obesity drug safety. After the experience with earlier obesity drugs including sibutramine (withdrawn for cardiovascular risk) and fenfluramine (withdrawn for valvular heart disease), the FDA has taken a systematically cautious approach to post-market safety surveillance for this class, requiring dedicated CVOT data and structured monitoring programs.
What Patients Taking Foundayo Should Know
If you are taking or considering Foundayo for weight management, the post-marketing study requirements do not indicate that the drug is unsafe. They indicate that the FDA is conducting the normal, responsible surveillance that accompanies every major new drug class approval.
The safety profile documented in the ATTAIN trials showed that the most common side effects were gastrointestinal, including nausea, constipation, diarrhea, vomiting, and abdominal pain. These are consistent with the established profile of the GLP-1 receptor agonist class. Hair loss was also reported and is typically temporary.
Key practical points:
- Foundayo should be discontinued at least 2 months before planned conception, consistent with guidance across the GLP-1 class. Effective contraception during treatment is recommended.
- Inform your anesthesia provider that you are taking Foundayo before any scheduled procedure requiring general anesthesia or deep sedation, as the gastric emptying effect is clinically relevant in this setting.
- Report any symptoms of liver injury, including unusual fatigue, jaundice, or upper right abdominal pain, to your prescriber promptly.
- Do not use Foundayo with other GLP-1 receptor agonists.
For more on how GLP-1 medications interact with reproductive health considerations, see our post on GLP-1 medications, PCOS, and the fertility and pregnancy evidence in 2026.
Sources
FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.
FDA approval letter: Foundayo (orforglipron) NDA approval letter. accessdata.fda.gov. April 1, 2026.
Lilly approval press release: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.
Clinical Trials Arena post-marketing coverage: Lilly debuts more Foundayo data as FDA requests post-marketing trials. clinicaltrialsarena.com. April 16, 2026.
Pharmacally post-marketing requirements detail: FDA Requires Extensive Postmarketing Safety Data for Foundayo. pharmacally.com. April 2026.
Foundayo drug history: Foundayo (orforglipron) FDA Approval History. drugs.com.
ACHIEVE-4 trial registration: NCT05803421. ClinicalTrials.gov.
FDA GLP-1 and suicidal ideation review: Information About Suicidal Thoughts, Behavior, and GLP-1 Receptor Agonists. FDA.gov.
Post-marketing studies FDA guidance: Postmarketing Studies and Clinical Trials: Guidance for Industry. FDA.gov.
GLP-1 gastric emptying clinical review: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.
PREA pediatric requirement: Pediatric Research Equity Act. FDA.gov.
DILI overview: Drug-Induced Liver Injury. StatPearls. NCBI.
ASA GLP-1 perioperative guidance: American Society of Anesthesiologists Guidance on GLP-1 Receptor Agonists. asahq.org.
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about obesity treatment, including whether Foundayo is appropriate for your situation, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals. |
|---|